Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

Type
Public
HQ
Cambridge, US
Founded
2000
Size (employees)
294 (est)
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square
Show all (1)
Report incorrect company information

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Financials

Merrimack Pharmaceuticals's revenue was reported to be $144.27 m in FY, 2016 which is a 61.6% increase from the previous period.
USD

Net income (Q1, 2018)

(17.8 m)

Market capitalization (14-Jun-2018)

120.4 m

Closing share price (14-Jun-2018)

9

Cash (31-Mar-2018)

34.3 m
Merrimack Pharmaceuticals's current market capitalization is $120.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

47.8 m102.8 m89.3 m144.3 m

Revenue growth, %

115%(13%)62%

Cost of goods sold

6.9 m

Gross profit

137.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

21.3 m33.7 m28.1 m

Cost of goods sold

1.9 m1 m

Gross profit

31.8 m27.1 m

Gross profit Margin, %

94%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

65.1 m35.7 m185.6 m21.5 m93.4 m

Accounts Receivable

5.9 m3.3 m6.5 m17.5 m100 k

Inventories

5.5 m4.7 m5.5 m14.6 m

Current Assets

166.6 m132.1 m201.4 m57.4 m95 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

105.5 m66.9 m77.8 m100.3 m28.8 m33.7 m56.4 m48.2 m21.5 m36.5 m17.2 m135.5 m34.3 m

Accounts Receivable

8.8 m12.2 m6.6 m2.6 m4.2 m1.8 m2.1 m15.6 m19.3 m22.2 m43 k43 k

Inventories

8.1 m12.3 m14.8 m

Current Assets

200.3 m138.9 m103.8 m162.1 m99.3 m74.9 m70.9 m160.7 m119 m89.6 m46.3 m141.6 m77.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(130.7 m)(83.6 m)(147.8 m)(153.5 m)470.9 m

Depreciation and Amortization

2.6 m3.2 m4.3 m6.2 m5.2 m

Inventories

4 m827 k(850 k)(9.7 m)

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(39.8 m)(27.8 m)(18.3 m)(28 m)(34.4 m)(22.9 m)(42.4 m)(38.7 m)(51 m)(30.3 m)(30.2 m)(17.8 m)

Depreciation and Amortization

1.2 m

Inventories

8.1 m12.3 m14.8 m

Cash From Operating Activities

(17.3 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Merrimack Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Merrimack Pharmaceuticals News and Updates

Report incorrect company information